Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor

References

• ArberDAOraziAHasserjianRThe 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemiaBlood2016127202391240527069254
   PubMed Web of Science ®Google Scholar
• BarbuiTThieleJVannucchiAMTefferiARationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisBlood Cancer J20155e33726832847
   PubMed Web of Science ®Google Scholar
• BaeEParkCJChoYUDifferential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosisInt J Lab Hematol201335662963623693053
   PubMed Web of Science ®Google Scholar
• TefferiARumiEFinazziGSurvival and prognosis among 1,545 patients with contemporary polychethemia vera: an international studyLeukemia20132791874188123739289
   PubMed Web of Science ®Google Scholar
• PassamontiFThieleJGhordonFA prognostic model to predict survival in 367 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and TreatmentBlood201212061197120122740446
   PubMed Web of Science ®Google Scholar
• GangatNCaramazzaDVaidyaRDIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion statusJ Clin Oncol201129439239721149668
   PubMed Web of Science ®Google Scholar
• VannucchiAGuglielminelliPRotunnoGMutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT projectBlood201412421405
   Web of Science ®Google Scholar
• TefferiAGuglielminelliPFinkeCIntegration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosisBlood201412421406
   Web of Science ®Google Scholar
• TefferiAMyeloproliferative neoplasms: a decade of discoveries and treatment advancesAm J Hematol2016911505826492355
   PubMed Web of Science ®Google Scholar
• SavonaMRAre we alterating the natural history of primary myelofibrosis?Leuk Res20143891004101224931396
   PubMed Web of Science ®Google Scholar
• Pinilla-IbarzJSweetKLCorrales-YepezGMKomrokjiRSRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms. Comparative lesson learnedOnco Targets Ther201694937495727570458
   PubMed Web of Science ®Google Scholar
• VerstovsekSKantarjianHMesaRASafety and efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in myelofibrosisN Engl J Med2010363121117112720843246
   PubMed Web of Science ®Google Scholar
• HarrisonCKiladjianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for myelofibrosisN Engl J Med2012366978779822375970
   PubMed Web of Science ®Google Scholar
• GregorySAMesaRAHoffmanRClinical and laboratory features of myelofibrosis and limitations of current therapiesClin Adv Hematol Oncol201199 Suppl 22116
   PubMedGoogle Scholar
• VerstovsekSMesaRAGotlibJCOMFORT-I investigatorsEfficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-IHaematologica2015100447948825616577
   PubMed Web of Science ®Google Scholar
• HarrisonCNVannucchiAMKiladjianJJLong-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisLeukemia20163081701170727211272
   PubMed Web of Science ®Google Scholar
• ChenXShuJGEmmTPharmacokinetics and pharmacodynamics of orally-administrated ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patientsClin Pharmacol Drug Dev201431344227128228
   PubMed Web of Science ®Google Scholar
• TalpazMPaquetteRAfrinLInterim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelets countsJ Hematol Oncol2013618124283202
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHCortesJVerstovsekSJanus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondNat Rev Drug Discov201110212714021283107
   PubMed Web of Science ®Google Scholar
• TefferiAPardananiASerious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosisMayo Clin Proc201186121188119122034658
   PubMed Web of Science ®Google Scholar
• TheocharidesAPLundbergPLakkarajuAKHomozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiencyBlood2016127253253325927013444
   PubMed Web of Science ®Google Scholar
• HeineAHeldSADaeckeSNThe JAK–inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivoBlood201312271192120223770777
   PubMed Web of Science ®Google Scholar
• RudolphJHeineAQuastTThe JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCKLeukemia201630102119212327220666
   PubMed Web of Science ®Google Scholar
• SchonbergKRudolphJVonnahmeMJAK inhibition impairs NK cell function in myeloproliferative neoplasmsCancer Res201575112187219925832652
   PubMed Web of Science ®Google Scholar
• MassaMRostiVCampanelliRRapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinibLeukemia201428244945124145312
   PubMed Web of Science ®Google Scholar
• KeohaneCKordastiSSiedlTJAK inhibition induces silencing of t helper cytokine secretion and a profound reduction in T regulatory cellsBr J Haematol20151711607326075866
   PubMed Web of Science ®Google Scholar
• Parampalli YajnanarayanaSStübigTCornezIJAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasmsBr J Haematol2015169682483325824483
   PubMed Web of Science ®Google Scholar
• Al-AliHKGriesshammerMle CoutrePSafety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1,144 patients in the JUMP trialHaematologica201610191065107327247324
   PubMed Web of Science ®Google Scholar
• SafdarAArmstrongDInfections in patients with hematologic neoplasms and hematologic stem cell transplantation: neutropenia, humoral, splenic defectsClin Infect Dis201153879880621890754
   PubMed Web of Science ®Google Scholar
• PeaFVialePThe antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?Clin Infect Dis200642121764177116705585
   PubMed Web of Science ®Google Scholar
• Levy HaraGKanjSSPaganiLTen key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of ChemotherapyInt J Antimicrob Agents201648323924627502752
   PubMed Web of Science ®Google Scholar
• Martí-CarvajalAJAnandVSolàIJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis (Review)Cochrane Database Syst Rev20154CD010298
   Google Scholar
• DeadmondMASmith-GagenJAChanging Incidence of Myeloproliferative Neoplasms: Trends and Subgroup Risk Profiles in the United States, 1973–2011J Cancer Res Clin Oncol2015141122131213825968903
   PubMed Web of Science ®Google Scholar
• HultcrantzMWilkesSRKristinssonSYRisk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden Between 1973 and 2005: a population-based studyJ Clin Oncol201533202288229526033810
   PubMed Web of Science ®Google Scholar
• LandmanGWArendSMvan DisselJTRuxolitinib can mask symptoms and signs of necrotizing fasciitisJ Infect201366329629723201967
   PubMed Web of Science ®Google Scholar
• KusanoYTeruiYUedaKHatakeKKlebsiella pneumoniae primary liver abscess associated with ruxolitinibAnn Hematol20169591561156227259987
   PubMed Web of Science ®Google Scholar
• ChenYHLeeCHPeiSNPulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosisLeuk Lymphoma20155651528152925213182
   PubMed Web of Science ®Google Scholar
• AbidiMZHaqueJVarmaPReactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinibCase Rep Hematol20162016238903827843657
   PubMedGoogle Scholar
• ShamilECunninghamDWongBLJaniPRuxolitinib associated tuberculosis presenting as a neck lumpCase Rep Infect Dis2015201528416826788384
   PubMedGoogle Scholar
• HopmanRKLawrenceSJOhSTDisseminated tuberculosis associated with ruxolitinibLeukemia20142881750175124625550
   PubMed Web of Science ®Google Scholar
• ColombaCRubinoRSiracusaLDisseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case reportBMC Res Notes2012555223039051
   PubMedGoogle Scholar
• PalandriFPolverelliNCataniLVianelliNRuxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallengeAnn Hematol201594351952025172457
   PubMed Web of Science ®Google Scholar
• BrancoBMetsuDDutertreMUse of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinibAnn Hematol20169571207120927113251
   PubMed Web of Science ®Google Scholar
• Von HofstenJJohnssonFMZetterbergMCytomegalovirus retinitis in a patient who received ruxolitinibN Engl J Med20163743296297
   PubMed Web of Science ®Google Scholar
• PalmasonRLindenORichterJCase-report: EBV driven lymphoproliferative disorder associated with ruxolitinibBMC Hematol2015151026167286
   PubMedGoogle Scholar
• KusanoYTeruiYUedaKHatakeKEpstein-Barr virus gastric ulcer associated with ruxolitinibAnn Hematol201695101741174227411541
   PubMed Web of Science ®Google Scholar
• TongLXJacksonJKerstetterJWorswickSDReactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatmentJ Am Acad Dermatol2014703e59e6024528917
   PubMed Web of Science ®Google Scholar
• WathersRMouleSMilojkovicDProgressive multifocal leukoencephalopathy associated with ruxolitinibN Engl J Med20133692197198
   Web of Science ®Google Scholar
• CoacciGMurgiaFPoddaLSolinasAAtzeniSLa NasaGReactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosisLeukemia201428122522723929216
   PubMed Web of Science ®Google Scholar
• ShenCHHwangCEChenYYChenCCHepatitis B virus reactivation associated with ruxolitinibAnn Hematol20149361075107624173089
   PubMed Web of Science ®Google Scholar
• YeoWJohnsonPJDiagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapyHepatology200643220922016440366
   PubMed Web of Science ®Google Scholar
• MalletVvan BommelFDoerigCManagement of viral hepatitis in patients undergoing haematopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukemia (ECIL-5)Lancet Infect Dis201616560661727599653
   PubMed Web of Science ®Google Scholar
• PerrilloRPGishRFalck-YtterYTAmerican Gastroenterological Association Institute Technical Review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapyGastroenterology20151481221.e3244.e325447852
   PubMed Web of Science ®Google Scholar
• StyczynskiJvan der VeldenWFoxCPSixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus Infections and post-transplant lymphoproliferative disorders in patients after allogenic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesHaematologica2016101780381127365460
   PubMed Web of Science ®Google Scholar
• Schmidt-HieberMSillingGSchalkECNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation) – Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)Ann Oncol20162771207122527052648
   PubMed Web of Science ®Google Scholar
• GoldbergRAReichelEOshryLJBilateral toxoplasmosis retinitis associated with ruxolitinibN Engl J Med2013369768168323944322
   PubMed Web of Science ®Google Scholar
• WyshamNGSullivanDRAlladaGAn opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitorChest201314351478147923648912
   PubMed Web of Science ®Google Scholar
• ChenCCChenYYHuangCECriptococcal meningoencephalitis associate with long-term use of ruxolitinibAnn Hematol201695236136226486358
   PubMed Web of Science ®Google Scholar
• LeeSCFeenstraJGeorghiouPRPneunomocystis jiroveci pneumonitis complicating ruxolitinib therapyBMJ Case Rep20142014pii bcr2014204950
   Google Scholar
• WilliamsKMAhnKWChenMThe incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTRBone Marrow Transplant201651457358026726945
   PubMed Web of Science ®Google Scholar
• GreenHPaulMVidalLProphylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trialsMayo Clin Proc20078291052105917803871
   PubMed Web of Science ®Google Scholar
• PerfectJRDismukesWEDromerFClinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of AmericaClin Infect Dis201050329132220047480
   PubMed Web of Science ®Google Scholar
• BrizendineKDBaddleyJWPappasPGPredictors of mortality and differences in clinical features among patients with cryptococcosis according to immune statusPLoS One201383e6043123555970
   PubMed Web of Science ®Google Scholar
• BaronEJMillerMWeinsteinMPA guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the infectious diseases society of America (IDSA) and the American Society for Microbiology (ASM)Clin Infect Dis2013574e22e12123845951
   PubMed Web of Science ®Google Scholar
• MarstonHDDixonDMKniselyJMPalmoreTNFauciASAntimicrobial resistanceJAMA2016316111193120427654605
   PubMed Web of Science ®Google Scholar
• PaczosaMKMecsasbJKlebsiella pneumoniae: going on the offense with a strong defenseMicrobiol Mol Biol Rev201680362966127307579
   PubMed Web of Science ®Google Scholar
• SingerMDeutschmanCSSeymourCWThe third international consensus definitions for sepsis and septic shock (Sepsis-3)JAMA2016315880181026903338
   PubMed Web of Science ®Google Scholar
• BryanJCVerstovsekSOvercoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibCancer Chemother Pharmacol20167761125114227017614
   PubMed Web of Science ®Google Scholar